NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: INDGN · data 2026-11-01
Indegene Limited
In plain words
Price: 6.4% below its 52-week high of ₹627.
Delivery: 64.4% of traded shares were kept for delivery over the last 10 sessions, against 56.4% over the last 60.
Latest results: a net profit of ₹112 cr for the quarter ended Sept 2026 (+10.0% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹4,131 cr |
| Net profit (last 12 months) | ₹411 cr |
| Sales growth, 3 years (yearly) | 15.0% |
| Profit growth, 3 years (yearly) | 14.7% |
At a glance
P/E 34.5, P/B 4.2, dividend yield 0.4%. Price relative to earnings and book value (low is cheaper, not better).
ROE 13.9%, ROCE 15.9%, operating margin 12.4%: how much profit it earns on the money it uses.
Debt/equity 0.05, Profit growth 14.7% and sales growth 15.0% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
INDGN Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹1,122.3 crore, up 39.6% YoY and up 5.6% QoQ.
Net profit was ₹112.3 crore, up 10% YoY and down 3.4% QoQ.
Operating margin was 16.5% (17.5% a year ago).
EPS was ₹4.67, up 9.6% YoY and down 3.5% QoQ.
INDGN के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹1,122.3 करोड़; पिछले साल की तुलना में 39.6% की बढ़त, पिछली तिमाही की तुलना में 5.6% की बढ़त।
शुद्ध मुनाफ़ा: ₹112.3 करोड़; पिछले साल की तुलना में 10% की बढ़त, पिछली तिमाही की तुलना में 3.4% की गिरावट।
ऑपरेटिंग मार्जिन: 16.5% (एक साल पहले 17.5%)।
EPS: ₹4.67; पिछले साल की तुलना में 9.6% की बढ़त, पिछली तिमाही की तुलना में 3.5% की गिरावट।
INDGNના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹1,122.3 કરોડ; ગયા વર્ષની સરખામણીએ 39.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 5.6% વધારો.
ચોખ્ખો નફો: ₹112.3 કરોડ; ગયા વર્ષની સરખામણીએ 10% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 3.4% ઘટાડો.
ઓપરેટિંગ માર્જિન: 16.5% (એક વર્ષ પહેલાં 17.5%).
EPS: ₹4.67; ગયા વર્ષની સરખામણીએ 9.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 3.5% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
17/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 60.0% over the last 20 sessions vs 53.0% in the 40 before (1.13x); shares delivered per day 0.54x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 5/15: 2 schemes hold it, about ₹142 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 3/15: Verdict "None", sustained score 61/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Deal ● Dividend
- 29 Oct 26Results Q2 FY27 results: profit +10.0% YoY -2.0% next session
- 8 Oct 26Deal Block deal: PI OPPORTUNITIES AIF V LLP bought ₹119.09 cr (net ₹0 cr) -4.4% next session
- 31 Jul 26Dividend Dividend ₹2.25 (ex-date) +5.9% next session
- 30 Jul 26Results Q1 FY27 results: profit −0.2% YoY -1.6% next session
- 29 Apr 26Results Q4 FY26 results: profit −32.2% YoY +0.2% next session
- 29 Jan 26Results Q3 FY26 results: profit −6.2% YoY +1.4% next session
- 30 Oct 25Results Q2 FY26 results: profit +11.3% YoY -1.1% next session
- 31 Jul 25Results Q1 FY26 results: profit +32.7% YoY +5.6% next session
- 13 Jun 25Dividend Dividend ₹2 (ex-date) -1.0% next session
- 28 Apr 25Results Q4 FY25 results: profit +21.7% YoY -1.6% next session
- 30 Jan 25Results Q3 FY25 results: net profit ₹109.7 cr -3.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹1,122 cr | ₹112 cr | +10.0% | 16.5% | 4.67 |
| Jun 2026 | ₹1,063 cr | ₹116 cr | -0.2% | 16.4% | 4.84 |
| Mar 2026 | ₹1,003 cr | ₹80 cr | -32.2% | 16.3% | 3.32 |
| Dec 2025 | ₹942 cr | ₹103 cr | -6.2% | 16.9% | 4.29 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | — | — | — | — |
| Foreign institutions (FII) | 12.40% | 9.91% | 10.27% | 11.48% |
| Domestic institutions (DII) | 15.82% | 8.74% | 8.30% | 8.07% |
| Mutual funds | 12.25% | 5.28% | 4.70% | 4.40% |
| Retail investors | 7.60% | 8.35% | 8.45% | 8.83% |
| Number of shareholders | 1,32,280 | 1,38,533 | 1,42,119 | 1,47,182 |
Common questions
What was Indegene Limited's latest quarterly profit?
Indegene Limited reported a net profit of ₹112 cr for the quarter ended Sept 2026 (+10.0% on the same quarter a year earlier), on revenue of ₹1,122 cr.
Is Indegene Limited debt-free?
Its latest reported debt-to-equity ratio is 0.05, which is very low.
What is Indegene Limited's P/E ratio?
About 34.5, based on the last 12 months' earnings and a price of ₹586.8 (data 2026-11-01).
What is the 52-week high and low of Indegene Limited?
The 52-week high is ₹627 and the 52-week low is ₹414.
Mutual funds holding Indegene Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 2 schemes holding about ₹142 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Innovative Opportunities Fund | SBI Mutual Fund | 1.73% | ₹89 cr |
| SBI Technology Opportunities Fund | SBI Mutual Fund | 1.27% | ₹53 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Indegene Limited | ₹586.8 | ₹14,161 cr | 34.5 | 4.2 | 13.9% | 15.9% | 0.05 | +7.5% |
| NATCO Pharma Limited | ₹782.4 | ₹15,350 cr | 12.4 | — | 16.9% | 15.6% | 0.08 | -4.8% |
| Jubilant Pharmova Limited | ₹923.8 | ₹14,729 cr | 41.7 | — | 6% | 6.5% | 0.51 | -19.6% |
| Marksans Pharma Limited | ₹306.2 | ₹13,896 cr | 26.9 | — | 15.2% | 16.3% | 0.11 | +66.7% |
| Corona Remedies Limited | ₹2,149.6 | ₹13,125 cr | 63.5 | 16.3 | 27.4% | 32.4% | 0.22 | +46.2% |
| Anupam Rasayan India Ltd. | ₹1,143.5 | ₹12,999 cr | 74.4 | — | 5.5% | 9% | 0.57 | +4.2% |
Compare INDGN with NATCOPHARM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open INDGN in NSE Scanner →